Beaumont

Beaumont Laboratory

Dearborn • Farmington Hills • Grosse Pointe • Royal Oak • Taylor • Trenton • Troy • Wayne

Laboratory Bulletin

Tissue Transglutaminase IgA Testing

Effective Date: February 7, 2023

Commencing February 7, 2023, Beaumont Laboratory will perform Tissue Transglutaminase (TTG) IgA testing for Corewell Health East sites using the Recombinant human TTG IgA enzyme-linked immunosorbent assay (ELISA). This method was independently validated by the Special Chemistry section of the Department of Pathology at Royal Oak. The new test will replace use of a first-generation immunoassay that uses native TTG isolated from human erythrocytes as the source of antigen for autoantibody detection.

Clinical Utility:

- First-line test for patients clinically suspected of having celiac disease.
- To support a diagnosis of dermatitis herpetiformis (DH) based on clinical and histologic findings.
- Monitoring response to gluten-free diet in patients with celiac disease and dermatitis herpetiformis.

Indication for Use & Test Interpretation:

- Semi-quantitative assessment of IgA against human TTG

Test Result (U/mL)	Interpretation
< 4.0	Negative
4.0-10.0	Weak Positive
> 10.0	Positive

Ordering Information:

Test Name	Epic Test Code
Celiac Disease Screen	LAB5751 Testing includes TTG IgA and total IgA
Tissue Transglutaminase Ab, IgA	LAB6912

- Specimen Collection Requirement: One gold-top Serum Separator Tube (SST)

For additional information, access the Laboratory Test Directory at:
http://beaumontlaboratory.com/test-lab-directory

Date submitted: January 17, 2023

Submitted By: Gabriel Maine, PhD
Caitlin Schein, MD System Medical Director, Clinical Chemistry